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Biometric Models in Men and Women 
Analyses were conducted in Mplus Version 8 (Muthén & Muthén, 2017). Univariate 
biometric models were fit for 1) prescription opioid misuse, 2) illicit opioid use, 3) prescription 
stimulant misuse, and 4) illicit stimulant use. Models estimated twin correlations and partitioned 
the variation in drug (mis)use liability into additive genetic (A; i.e., aggregate effects of genes), 
shared environmental (C; i.e., influence that makes twins similar), and unique (nonshared) 
environmental (E; i.e., influence that makes twins different) variance components. Thresholds 
(prevalences) were allowed to differ across sex. Sex differences were examined within biometric 
models. Quantitative sex differences (i.e., differences in the proportion of A, C, and E) were 
examined by constraining parameter estimates for men and women to be equal; qualitative sex 
differences (i.e., different genetic or environmental source of liability), were tested by 
constraining the genetic correlation or the shared environmental correlation for opposite-sex twin 
pairs to 0.5 (i.e., the genetic correlation for same-sex twin pairs) and 1 (i.e., the shared 
environmental correlation assumed across zygosity), respectively. Significant deterioration in 




Twin correlations of prescription misuse and illicit use in men and women 
 
 Opioids Stimulants 
 Univariate Correlations Univariate Correlations 
Zygosity Sex Prescription Misuse Illicit Use Prescription Misuse Illicit Use 
 r [95% CI] r [95% CI] r [95% CI] r [95% CI] 
MZ 
M .22 [.01, .48] .31 [.12, .48]* .73 [.55, .84]** .82 [. 69, .92]** 
F .47 [.30, .66]** .86 [.55, .97]** .80 [.67, .88]** .73 [.58, .83]** 
DZ 
M .19 [.01, .48] .30 [.16, .47]** .51 [.28, .73]* .49 [.39, .67]** 
F .25 [.14, .43]** .85 [.62, .96]** .41 [.33, .48]** .57 [.42, .72]** 
OS  .16 [.00, .35] .50 [.36, .71]** .14 [.00, .30] .27 [.00, .47] 
  Bivariate Correlations Bivariate Correlations 
  Prescription and Illicit Opioid (Mis)Use Prescription and Illicit Stimulant (Mis)Use 
Zygosity Sex Within-Twin Cross-Twin Within-Twin Cross-Twin 
 r [95% CI] r [95% CI] r [95% CI] r [95% CI] 
MZ 
M .53 [.18, .73]** .51 [.32, .69]** .87 [.78, .92]** .69 [.51, .80]** 
F .52 [.00, .75] .43 [-.07, .70] .88 [.82, .93]** .66 [.55, .76]** 
DZ 
M .74 [.28, .91]** .38 [.07, .60]* .92 [.83, .96]** .48 [.06, .63]** 
F .57 [.21, .77]** .18 [-.09, .42] .85 [.76, .90]** .42 [.19, .54]** 
OS 
 
(M) .51 [-.06, .81]* .19 [.01, .31]*a .90 [.77, .94]** .15 [-21, .37]a 
(F) .36 [.19, .52]** -.11 [-.28, .06]b .91 [.78, .96]** .24 [-.05, .44]b 
  Prescription Opioid and Stimulant Misuse Illicit Opioid and Stimulant Use 
Zygosity Sex Within-Twin Cross-Twin Within-Twin Cross-Twin 
  r [95% CI] r [95% CI] r [95% CI] r [95% CI] 
MZ 
M .41 [.17, .55]** .32 [.10, .45]** .67 [.53, .76]** .61 [.45, .76]** 
F .33 [.16, .47]** .29 [.11, .45]** .74 [.62, .84]** .61 [.38, .76]** 
DZ 
M .57 [.29, .71]** .21[-.06, .52] .61 [.28, .88]** .22 [-.17, .47] 
F .31 [.15, .49]** .06 [-.12, .24] .80 [.66, .85]** .67 [.40, 80]** 
OS 
 
(M) .42 [.22, .60]** .24 [-.14, .50]a .71 [.57, .79]** .21 [.13, .33]*a 
(F) .50 [-.08, .69] -.23 [-.50, .10]b .18 [.00, .34] .26 [-.23, .61]b 
Note. OS=dizygotic opposite sex pairs; a male twin prescription misuse correlated with female twin illicit use, b male twin illicit use 
correlated with female twin prescription misuse; **p<.001, *p<.01. 
Table S2 
 
Twin correlations between three forms of stimulant drug use in men and women 
 
  Ecstasy Use  Methamphetamine Use 
 Zyg Sex Within-Twin Cross-Trait  Cross-Twin Cross-Trait  Within-Twin Cross-Trait  Cross-Twin Cross-Trait 













































e .65 [.42, .79]** 
F .87 [.81, .92]** .66 [.53, .76]** .84 [.76, .89]** .65 [.40, .78]** 
DZ 
M .91 [.83, .96]** .49 [.24, .68]** .82 [.71, .90]** .18 [-.18, .47] 
F .85 [.77, .91]** .42 [.22, .56]** .76 [.61, .85]** .00 [-.23, .24] 
OS 
(M) .90 [.81.95]** .15 [-.11, .37] .73 [.49, 85]** .36 [.01, .66] 
(F) .91 [.79, .96]**  .25 [.01, .46]*  .59 [.22, .83]**  .07 [-.32, .37] 
 Zyg Sex Cross-Twin Within-Trait  Within-Twin Cross-Trait  Cross-Twin Within-Trait  Cross-Twin Cross-Trait 






























.72 [.54, .84]** 
 F .73 [.62, .83]** .83 [.75, .88]** .71 [.31, .88]** .67 [.44, .80]** 
DZ M .50 [.38, .72]** .80 [.68, .88]** .32 [.10, .47]** .30 [-.02, .60] 
 F .57 [.40, .71]** .74 [.61, .83]** .36 [.16, .45]** .17 [-.11. .47] 
OS (M) .28 [.04, .47]* .77 [.59., 86]** .14 [.00, .36] .31 [-.06, .61] 
 (F)   .58 [.22, 97]**    .04 [-.32, 39] 




Variation in opioid use propensity attributable to attributable to additive genetic (a2), shared environmental (c2), and unique 
environmental (e2) factors in men and women 
 
   Men Women Model Fit 
 rg a2 c2 e2 a2 c2 e2 2 df p 
Model Prescription Misuse 
1a. ACE free, rg DZO free 




.00, .53 .00, .49 .51, 1.00 .02, .65 .00, .46 .34, .70    
2a. ACE free, rg DZO fixed 
Estimate .50 .08 .14 .78 .44 .03 .53 25.98 28 .57 
95% CI fixed .00, .44 .00, .39 .56, .99 .07, .61 .00, .45 .38, .70    
3a. ACE fixed, rg DZO free 




.06, .50 .00, .36 .48, .73 .06, .50 .00, .36 .48, .73    
4a. ACE fixed, rg DZO fixed 
Estimate 0.50 .40 .01 .59 .40 .01 .59 27.92 30 .57 
95% CI fixed .12, .51 .00, .36 .50, .73 .12, .51 .00, .36 .50, .73    
Model Illicit Use 
1b. ACE free, rg DZO free 
Estimate .29 .02 .29 .69 .04 .83 .14 26.17 27 .51 
95% CI .10, 
.48 
.00, .36 .16, .54 .46, .82 .00, .39 .56, .96 .01, .37    
2b. ACE free, rg DZO fixed 
Estimate .50 .03 .28 .69 .00 .86 .14 25.90 28 .58 
95% CI fixed .00, .69 .15, .54 .35, .84 .00, .52 .56, .96 .02, .40    
3b. ACE fixed, rg DZO free 




.00, .00 .53, .81 .19, .46 .00, .00 .53, .81 .19, .46    
4b. ACE fixed, rg DZO fixed 
Estimate 0.50 .00 .71 .29 .00 .71 .29 37.19 30 .17 
95% CI fixed .00, .04 .53, .81 .16, .45 .00, .04 .53, .81 .16, .45    
Note. All models include age as a covariate; bold indicates significant parameter estimate; bolded model=preferred solution; 
DZO=opposite-sex dizygotic twins; CI=confidence interval; rg=correlation between genetic influences in opposite sex twin pairs; values 
may not add to 1 due to rounding error. 
Table S4 
 
Variation in stimulant use propensity  attributable to additive genetic (a2), shared environmental (c2), and unique environmental (e2) factors in 
men and women 
 
   Men Women Model Fit 
 rg a2 c2 e2 a2 c2 e2 2 df p 
Model Prescription Misuse 
1a. ACE free, rg DZO free 
Estimate .15 .46 .28 .27 .80 .01 .20 20.75 27 .80 
95% CI .00, .50 .02, .82 .00, .72 .16, .45 .66, .89 .00, .23 .12, .31    
2a. ACE free, rg DZO fixed 
Estimate .50 .24 .46 .30 .80 .00 .20 20.95 28 .82 
95% CI fixed .00, .76 .00, .75 .17, .52 .67, .89 .00, .00 .10, .31    
3a. ACE fixed, rg DZO free 
Estimate .18 .78 .01 .21 .78 .01 .21 22.12 29 .82 
95% CI .00, .50 .57, .87 .00, .26 .14, .30 .57, .87 .00, .26 .14, .30    
4a. ACE fixed, rg DZO fixed 
Estimate 0.50 .78 .00 .22 .78 .00 .22 24.80 30 .73 
95% CI fixed .68, .84 .00, .00 .16, .32 .68, .84 .00, .00 .16, .32    
Model Illicit Use 
1b. ACE free, rg DZO free 
Estimate .00 .65 .17 .18 .31 .42 .27 26.73 27 .48 
95% CI nc .17, .89 .00, .62 .08, .33 .00, .67 .08, .69 .18, .39    
2b. ACE free, rg DZO fixed 
Estimate .50 .83 .00 .18 .29 .44 .28 27.62 28 .48 
95% CI fixed .62, .94 .00, .75 .08, .31 .00, .69 .03, .67 .17, .39    
3b. ACE fixed, rg DZO free 
Estimate .00 .48 .29 .23 .48 .29 .23 28.30 29 .50 
95% CI nc .29, .69 .10, .45 .15, .31 .29, .69 .10, .45 .15, .31    
4b. ACE fixed, rg DZO fixed 
Estimate 0.50 .58 .19 .24 .58 .19 .24 33.20 30 .31 
95% CI fixed .29, .80 .00, .42 .16, .32 .29, .80 .00, .42 .16, .32    
Note. Bold indicates significant parameter estimate; bolded model=preferred solution; DZO=opposite-sex dizygotic twins; CI=confidence 
interval; rg=correlation between genetic influences in opposite sex twin pairs; nc=not calculable (estimate reached boundary condition); values 
may not add to 1 due to rounding error. 
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Variation in opioid and stimulant use propensity  attributable to additive genetic (a2), shared 
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